Home > Oncology > ESMO 2019 > GI Cancers > Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By
Prof. Scott Kopetz (MD Anderson Cancer Center, Houston, USA)
Conference
ESMO 2019
Trial
Phase 3, BEACON CRC

The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC phase 3 clinical trial.

Prof. Scott Kopetz (MD Anderson Cancer Center, Houston, USA) presented the international collaboration, which included >200 centres worldwide in this open label, three-arm randomised clinical trial. A total of 665 patients with BRAF V600E-mutant mCRC who had progressed after one or two prior regimens in the metastatic setting were randomised to receive triplet therapy, doublet therapy (encorafenib and cetuximab), or the investigator’s choice of irinotecan or folinic acid, fluoruracil and irinotecan (FOLFIRI) and cetuximab [1]. BRAF mutations are estimated to occur in up to 15% of patients with mCRC, with V600E being the most ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on